Skip to content
AMR Drug RepurposingSmart Screeningresearch prototype

Grazoprevir

FDA-approved product (tablet, oral).

Registered studies
50+
Lab records
0
Pathogens at ≥40%
4 of 4

Chemical structure

Chemical structure of Grazoprevir
A drawing shows what the molecule is, not what it does.

Existing / approved use

Documented · FDA, WHO, ChEMBL

Approved for

  • Chronic hepatitis C virus infection

Indications ChEMBL records as approved, from FDA and DailyMed labels. Label ↗

WHO therapeutic group
Antivirals for treatment of hcv infections
Anti-infective classification
Classified as another kind of anti-infective (for example an antifungal, antiviral or antiparasitic medicine).WHO ATC J05AP11

Repurposing investigation

This medicine is being investigated here for AI-predicted antimicrobial activity against E. coli, MRSA, K. pneumoniae and M. tuberculosis. It was surfaced computationally for further investigation; it is not an established treatment for these infections.

AI-predicted activity

AI prediction · nothing measured
  • MRSA61.9% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • E. coli46.2% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • K. pneumoniae44.6% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • M. tuberculosis57.6% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.

A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.

Evidence

Clinical and experimental

Documented evidence

Clinical

50+registered studies name this medicine, for any condition. The registry search keeps the first 50, so there may be more. See them below.

Experimental

No evidence found

No laboratory measurement against the four pathogens in the ChEMBL records loaded here.

Open Grazoprevir in ChEMBL Registered studies below

Docking

Computational · nothing measured

Dihydrofolate reductase ↗ (E. coli)

Not yet docked: queued in the docking rundetails

KPC-2 carbapenemase ↗ (K. pneumoniae)

Not yet docked: queued in the docking rundetails

Enoyl-ACP reductase (InhA) ↗ (M. tuberculosis)

Not yet docked: queued in the docking rundetails

Dihydrofolate reductase ↗ (MRSA)

Not yet docked: queued in the docking rundetails

AutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.

Other medicines to investigate

AI prediction · nothing measured

Other repurposing candidates: approved medicines besides Grazoprevir with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.

Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.

Registered studies

A registration describes a study; it does not establish a positive result.

  • Efficacy and Tolerability of Grazoprevir and Elbasvir in Patients With Chronic Genotype 1 HCV and HIV Co-infection

    NCT03098121 · start 2017-10-20

    Registered record
    Registry ID
    NCT03098121
    Conditions
    Chronic Hepatitis C
    Interventions
    grazoprevir and elbasvir
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Completed
    Start
    2017-10-20
    Completion
    2018-11-30
    Enrolment
    40

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionChronic Hepatitis C
    Interventiongrazoprevir and elbasvir
    PhasePhase 4
    Registry statusCompleted

  • Efficacy and Safety of Elbasvir (MK-8742) + Grazoprevir (MK-5172) in Treatment-Naïve/Treatment-Experienced (TN/TE) French Participants With Hepatitis C Virus (HCV) Genotype 4 (GT4) Infection (MK-5172-096)

    NCT03111108 · start 2017-06-20

    Registered record
    Registry ID
    NCT03111108
    Conditions
    Hepatitis C Virus (HCV) Infection
    Interventions
    EBR/GZR (50 mg/100 mg) FDC
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Completed
    Start
    2017-06-20
    Completion
    2018-10-15
    Enrolment
    117

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHepatitis C Virus (HCV) Infection
    InterventionEBR/GZR (50 mg/100 mg) FDC
    PhasePhase 4
    Registry statusCompleted

  • Retrospective Efficacy and Safety Study With Elbasvir/Grazoprevir in HCV-infected Patients With Chronic Kidney Disease

    NCT03145623 · start 2017-06-02

    Registered record
    Registry ID
    NCT03145623
    Conditions
    Hepatitis C; Chronic Kidney Diseases
    Interventions
    Elbasvir and Grazoprevir
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Completed
    Start
    2017-06-02
    Completion
    2017-12-31
    Enrolment
    100

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHepatitis C; Chronic Kidney Diseases
    InterventionElbasvir and Grazoprevir
    PhaseNot recorded
    Registry statusCompleted

  • Hepatitis C Treatment in PWIDs: MAT or Syringe Exchange Assisted-therapy vs Standard of Care

    NCT03093415 · start 2017-05-30

    Registered record
    Registry ID
    NCT03093415
    Conditions
    Hepatitis C; Substance Use Disorders; Substance Abuse, Intravenous
    Interventions
    elbasvir-grazoprevir (50 mg/100 mg)
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Completed
    Start
    2017-05-30
    Completion
    2019-06-06
    Enrolment
    100

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHepatitis C; Substance Use Disorders; Substance Abuse, Intravenous
    Interventionelbasvir-grazoprevir (50 mg/100 mg)
    PhasePhase 4
    Registry statusCompleted

  • HCV Treatment Immune Response With Grazoprevir/Elbasvir Before or After Renal Transplant

    NCT02902120 · start 2017-05-01

    Registered record
    Registry ID
    NCT02902120
    Conditions
    Hepatitis C; Renal Insufficiency, Chronic; Disorder of Transplanted Kidney
    Interventions
    Post-transplant Grazoprevir and Elbasvir
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Completed
    Start
    2017-05-01
    Completion
    2022-06-08
    Enrolment
    21

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHepatitis C; Renal Insufficiency, Chronic; Disorder of Transplanted Kidney
    InterventionPost-transplant Grazoprevir and Elbasvir
    PhasePhase 4
    Registry statusCompleted

  • the Effect of Grazoprevir/Elbasvir and TACE vs. TACE Alone in Prolonging Survival of Patients With Non-resectable HCV Associated HCC.

    NCT03110055 · start 2017-05-01

    Registered record
    Registry ID
    NCT03110055
    Conditions
    HCV, HCC
    Interventions
    Grazoprevir/Elbasvir; Medical records; Transarterial Chemoembolization
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Unknown
    Start
    2017-05-01
    Completion
    2019-05-01
    Enrolment
    20

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHCV, HCC
    InterventionGrazoprevir/Elbasvir; Medical records; Transarterial Chemoembolization
    PhaseNot applicable
    Registry statusUnknown

  • Efficacy of GZR/EBR in Early Chronic Hepatitis C in HIV/HCV Co-infected Patients

    NCT02897596 · start 2017-04-28

    Registered record
    Registry ID
    NCT02897596
    Conditions
    Hepatitis C; HIV
    Interventions
    Grazoprevir 100 mg/d 8 weeks; Elbasvir 50 mg/d 8 weeks; Grazoprevir 100 mg/d 12 weeks; Elbasvir 50 mg/d 12 weeks
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Unknown
    Start
    2017-04-28
    Completion
    2019-10-30
    Enrolment
    62

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHepatitis C; HIV
    InterventionGrazoprevir 100 mg/d 8 weeks; Elbasvir 50 mg/d 8 weeks; Grazoprevir 100 mg/d 12 weeks; Elbasvir 50 mg/d 12 weeks
    PhasePhase 3
    Registry statusUnknown

  • A Study for G1b CHC Patients With CKD-3 Treated With Grazoprevir Plus Elbasvir

    NCT03144635 · start 2017-04-01

    Registered record
    Registry ID
    NCT03144635
    Conditions
    Hepatitis C Viral; Chronic Kidney Disease stage3
    Interventions
    Grazoprevir plus Elbasvir
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Completed
    Start
    2017-04-01
    Completion
    2018-09-20
    Enrolment
    80

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHepatitis C Viral; Chronic Kidney Disease stage3
    InterventionGrazoprevir plus Elbasvir
    PhasePhase 4
    Registry statusCompleted

  • Study to Investigate the Efficacy of Elbasvir/Grazoprevir Fixed-Dose Combination for 8 Weeks in Treatment-Naïve, HCV GT1b-Infected Patients, With Non-severe Fibrosis

    NCT02973503 · start 2017-01-11

    Registered record
    Registry ID
    NCT02973503
    Conditions
    Chronic HCV Infection
    Interventions
    Elbasvir/Grazoprevir Fixed Dose Combination
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2017-01-11
    Completion
    2019-04
    Enrolment
    117

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionChronic HCV Infection
    InterventionElbasvir/Grazoprevir Fixed Dose Combination
    PhasePhase 3
    Registry statusCompleted

  • Pembrolizumab (MK-3475) in Hepatocellular Carcinoma

    NCT02940496 · start 2016-12-09

    Registered record
    Registry ID
    NCT02940496
    Conditions
    BCLC Stage B Hepatocellular Carcinoma; BCLC Stage C Hepatocellular Carcinoma; Hepatitis C Infection; Refractory Liver Carcinoma; Stage III Hepatocellular Carcinoma AJCC v7; Stage IIIA Hepatocellular Carcinoma AJCC v7; Stage IIIB Hepatocellular Carcinoma AJCC v7; Stage IIIC Hepatocellular Carcinoma AJCC v7; Stage IV Hepatocellular Carcinoma AJCC v7; Stage IVA Hepatocellular Carcinoma AJCC v7; Stage IVB Hepatocellular Carcinoma AJCC v7
    Interventions
    Elbasvir/Grazoprevir; Laboratory Biomarker Analysis; Pembrolizumab; Ribavirin
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2016-12-09
    Completion
    2023-08-09
    Enrolment
    15

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionBCLC Stage B Hepatocellular Carcinoma; BCLC Stage C Hepatocellular Carcinoma; Hepatitis C Infection; Refractory Liver Carcinoma +7 more
    InterventionElbasvir/Grazoprevir; Laboratory Biomarker Analysis; Pembrolizumab; Ribavirin
    PhasePhase 2
    Registry statusCompleted

  • Pilot Study Evaluate Efficacy of Grazoprevir + Elbasvir for 12 or 16 Weeks in Liver Transplant Recipients.

    NCT02890719 · start 2016-08-03

    Registered record
    Registry ID
    NCT02890719
    Conditions
    Liver Transplantation; Hepatitis C
    Interventions
    Grazoprevir 100 mg/day; Elbasvir 50 mg/d; Grazoprevir 100 mg/day; Elbasvir 50 mg/day; Ribavirin 1200 mg/day
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Withdrawn
    Start
    2016-08-03
    Completion
    2017-06-01
    Enrolment
    0

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionLiver Transplantation; Hepatitis C
    InterventionGrazoprevir 100 mg/day; Elbasvir 50 mg/d; Grazoprevir 100 mg/day; Elbasvir 50 mg/day +1 more
    PhasePhase 3
    Registry statusWithdrawn

  • Exploring Renal Transplants Using Hepatitis C Infected Donors for HCV-negative Recipients

    NCT02781649 · start 2016-07-20

    Registered record
    Registry ID
    NCT02781649
    Conditions
    End-Stage Renal Disease; Hepatitis C
    Interventions
    Zepatier; Ribavirin; Sofosbuvir
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Completed
    Start
    2016-07-20
    Completion
    2018-01-01
    Enrolment
    10

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionEnd-Stage Renal Disease; Hepatitis C
    InterventionZepatier; Ribavirin; Sofosbuvir
    PhasePhase 4
    Registry statusCompleted

  • Swiss HCVree Trial

    NCT02785666 · start 2016-06

    Registered record
    Registry ID
    NCT02785666
    Conditions
    Hepatitis C; HIV
    Interventions
    grazoprevir/elbasvir, ribavirin; Behavioural Intervention
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2016-06
    Completion
    2018-08
    Enrolment
    150

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHepatitis C; HIV
    Interventiongrazoprevir/elbasvir, ribavirin; Behavioural Intervention
    PhasePhase 3
    Registry statusCompleted

  • Study to Investigate Tolerability and Efficacy of MK5172 / MK8742 Without Ribavirin for 12 Weeks in Patients With Chronic HCV G1b Infection With Compensated Cirrhosis

    NCT02732405 · start 2016-05

    Registered record
    Registry ID
    NCT02732405
    Conditions
    Hepatitis C; Compensated Cirrhosis
    Interventions
    MK5172 /MK8742
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Unknown
    Start
    2016-05
    Completion
    2017-03
    Enrolment
    120

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHepatitis C; Compensated Cirrhosis
    InterventionMK5172 /MK8742
    PhasePhase 3
    Registry statusUnknown

  • Dutch Acute HCV in HIV Study (DAHHS-2): Grazoprevir/Elbasvir for Acute HCV

    NCT02600325 · start 2016-02

    Registered record
    Registry ID
    NCT02600325
    Conditions
    Acute Hepatitis C; Human Immunodeficiency Virus; Hepatitis C
    Interventions
    Grazoprevir/Elbasvir 100mg/50mg
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2016-02
    Completion
    2019-01-11
    Enrolment
    80

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAcute Hepatitis C; Human Immunodeficiency Virus; Hepatitis C
    InterventionGrazoprevir/Elbasvir 100mg/50mg
    PhasePhase 3
    Registry statusCompleted